Assistant Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
Oncology
Dr. Panagiotis Konstantinopoulos, MD
|
|
Give Review
Panagiotis Konstantinopoulos works in the field of Oncology. He studied medicine at SUNY Upstate Medical University. He has 1 awards "Meaningful Use Stage 1 Certification". Panagiotis Konstantinopoulos is also a published doctor. He has 78 paper published. The most recent paper is: Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. He is registered with Medicare and accepts Medicare payments.
Publications
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high ...
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
- Resistance to therapy in BRCA2 mutant Cells due to loss of the nucleosome remodeling factor CHD4.
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
- Complications of pelvic radiation in patients treated for gynecologic Malignancies.
- POLE mutations as an alternative pathway for microsatellite instability in endometrial Cancer: Implications for Lynch syndrome testing.
- Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma.
- PARP inhibitors in ovarian Cancer: Current status and future promise.
- Pathologic and gene expression features of metastatic melanomas to the brain.
- Postpartum cerebral angiopathy: an important diagnostic consideration in the postpartum period.
- The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
- Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial Cancers.
- Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era.
- PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenoCarcinomas.
- 17-AAG: mechanisms of antitumour activity.
- FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
- NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma ''on/off'' switches and induction of CBP in colon adenoCarcinomas: correlation with COX-2 expression.
- Chromatin-modulating agents as epigenetic antiCancer drugs--''the die is cast''.
- Babesiosis masquerading as recurrent immune thrombocytopenic purpura in a splenectomized patient.
- Images in HIV/AIDS. HIV-associated squamous cell Carcinoma of the anus.
- Molecular Medicine and biomedical education: reshaping our mission.
- The potential of proteasome inhibition in the treatment of colon Cancer.
- HIV-associated Anal squamous cell cancer: an otherwise preventable disease.
- Morphologic and immunophenotypic evidence of in-Situ Kaposi''s sarcoma.
- Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites--the unknown role of underlying HIV infection.
- Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for antiCancer therapy.
- The role of STATs in Lung carcinogenesis: an emerging target for novel therapeutics.
- Management of AIDS-related Kaposi''s sarcoma.
- The activator protein-1 transcription factor in respiratory epithelium carcinogenesis.
- HIV-associated intramammary lymphadenopathy.
- Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges.
- Investigational agents for treatment of AIDS-related Kaposi''s sarcoma.
- Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis.
- SUMO and estrogen receptors in breast Cancer.
- Effect of aspirin use on thiazolidinediones and cardiovascular events.
- Gene-expression profiling in epithelial ovarian Cancer.
- Statins in patients with chronic Kidney disease: a double-edged sword?
- Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian Cancer.
- Educational and social-ethical issues in the pursuit of molecular medicine.
- Leiomyosarcoma of the prostate: case report and review of 54 previously published cases.
- Altered proliferation and differentiation properties of primary mammary epithelial Cells from BRCA1 mutation carriers.
- Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder Cancer treated with adjuvant BCG immunotherapy.
- The role of statins in chronic Kidney disease (CKD): friend or foe?
- Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
- Rosuvastatin in patients undergoing hemodialysis.
- Generation of tumor-specific T lymphocytes using dendritic Cell/tumor fusions and anti-CD3/CD28.
- Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.
- Molecular networks in respiratory epithelium Carcinomas.
- Systemic therapy of metastatic bladder Cancer in the molecular era: current status and future promise.
- Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian Cancer.
- Integrated Analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.
- Seeing the future of Cancer-associated transcription factor drug targets.
- Keap1 mutations and Nrf2 pathway activation in epithelial ovarian Cancer.
- Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian Cancer.
- Just another simple case of infectious mononucleosis?
- Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
- The molecular basis of retinoids'' use in breast Cancer chemoprevention.
- Focus on acetylation: the role of histone deacetylase inhibitors in Cancer therapy and beyond.
- Post-translational modifications and regulation of the RAS superfamily of GTPases as antiCancer targets.
- Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
- Protein electrophoresis and immunoglobulin Analysis in HIV-infected patients.
- Trastuzumab--mechanism of action and use.
- EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenoCarcinomas paralleling expression of COX-2 and VEGF.
- Matrix metalloproteinase inhibitors as antiCancer agents.
- Anti-Yo antibody associated with occult fallopian tube Carcinoma.
- Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial.
- Expression of the 27-kDa heat shock protein (HSP27) in gastric Carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significa...
- ErbB/HER receptor family in breast Cancer--the more we search the more we learn.
- Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in Cancer therapeutics.
- Acquired immunodeficiency syndrome related Kaposi''s sarcoma eroding the maxillary bone.
- Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric Cancer.
- Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenoCarcinoma paralleling the tumour''s dedifferentiation.
- Molecular pathogenesis of non muscle-invasive bladder Cancer: implications for novel targeted therapies.
- Intriguing issues of EGFR targeting in head and neck Cancer.
- Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube Cancer.
- Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer.
Schools
Med School University Of Patras
SUNY Upstate Syracuse
Beth Israel Deaconess Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Beth Israel Deaconess Medical Center -
SUNY Upstate Medical University
Hospital
-
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1649218942 | |
| NPPES Provider LastName | KONSTANTINOPOULOS | |
| NPPES Provider FirstName | PANAGIOTIS | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 143.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 7.69 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649218942 |
| Last Name Of The Provider | KONSTANTINOPOULOS |
| First Name Of The Provider | PANAGIOTIS |
| View All |
Similar Doctors
|
|
Dr. Rebecca S. Heist, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald W. Takvorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel L. Yung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rameen Beroukhim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eyal C. Attar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rochelle G. Scheib, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann S. Lacasce, MD
This Doctor is OpenDoctor Recommended.
|